IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive

Molecular Immunology

Volumn 49, Issue 1-2, 2011, Pages 253-259

  Godin Ethier, Jessica ^a   Hanafi, Laïla Aïcha ^a   Duvignaud, Jean Baptiste ^b,c   Leclerc, Denis ^b   Lapointe, Réjean ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Amino acid metabolism; CD40L; Enzyme; IFN ; Immunosuppression

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; IMIQUIMOD; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; MESSENGER RNA; TOLL LIKE RECEPTOR; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION;

B-LYMPHOCYTES; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHOCYTE ACTIVATION; MICROSCOPY, FLUORESCENCE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 82455198547     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.08.017     Document Type: Article

References (37)

1. Ball H.J., Sanchez-Perez A., Weiser S., Austin C.J., Astelbauer F., Miu J., McQuillan J.A., Stocker R., Jermiin L.S., Hunt N.H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007, 396:203-213.
2. Booth J.S., Buza J.J., Potter A., Babiuk L.A., Mutwiri G.K. Co-stimulation with TLR7/8 and TLR9 agonists induce down-regulation of innate immune responses in sheep blood mononuclear and B cells. Dev. Comp. Immunol. 2010, 34:572-578.
3. Fallarino F., Grohmann U., Vacca C., Bianchi R., Orabona C., Spreca A., Fioretti M.C., Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9:1069-1077.
4. Fallarino F., Vacca C., Orabona C., Belladonna M.L., Bianchi R., Marshall B., Keskin D.B., Mellor A.L., Fioretti M.C., Grohmann U., Puccetti P. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int. Immunol. 2002, 14:65-68.
5. Fallarino F., Grohmann U., You S., McGrath B.C., Cavener D.R., Vacca C., Orabona C., Bianchi R., Belladonna M.L., Volpi C., Santamaria P., Fioretti M.C., Puccetti P. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006, 176:6752-6761.
6. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., Mellor A.L., Munn D.H., Antonia S.J. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 2002, 101:151-155.
7. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196:459-468.
8. Hwu P., Du M.X., Lapointe R., Do M., Taylor M.W., Young H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 2000, 164:3596-3599.
9. Inoue S., Leitner W.W., Golding B., Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006, 66:7741-7747.
10. Johnson B.A., Kahler D.J., Baban B., Chandler P.R., Kang B., Shimoda M., Koni P.A., Pihkala J., Vilagos B., Busslinger M., Munn D.H., Mellor A.L. B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10644-10648.
11. Kai S., Goto S., Tahara K., Sasaki A., Tone S., Kitano S. Indoleamine 2,3-dioxygenase is necessary for cytolytic activity of natural killer cells. Scand. J. Immunol. 2004, 59:177-182.
12. Kyewski B., Klein L. A central role for central tolerance. Annu. Rev. Immunol. 2006, 24:571-606.
13. Lapointe R., Bellemare-Pelletier A., Housseau F., Thibodeau J., Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003, 63:2836-2843.
14. Leclerc D., Beauseigle D., Denis J., Morin H., Pare C., Lamarre A., Lapointe R. Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J. Virol. 2007, 81:1319-1326.
15. Löb S., Konigsrainer A., Schafer R., Rammensee H.G., Opelz G., Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008, 111:2152-2154.
16. Mellor A.L., Baban B., Chandler P.R., Manlapat A., Kahler D.J., Munn D.H. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 2005, 175:5601-5605.
17. Metz R., DuHadaway J.B., Kamasani U., Laury-Kleintop L., Muller A.J., Prendergast G.C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound d-1-methyl-tryptophan. Cancer Res. 2007, 67:7082-7087.
18. Mills D.M., Cambier J.C. B lymphocyte activation during cognate interactions with CD4+ T lymphocytes: molecular dynamics and immunologic consequences. Semin. Immunol. 2003, 15:325-329.
19. Morse D.L., Carroll D., Weberg L., Borgstrom M.C., Ranger-Moore J., Gillies R.J. Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal. Biochem. 2005, 342:69-77.
20. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
21. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189:1363-1372.
22. Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., Messina J.L., Chandler P., Koni P.A., Mellor A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 2004, 114:280-290.
23. Munn D.H., Sharma M.D., Mellor A.L. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 2004, 172:4100-4110.
24. Musso T., Gusella G.L., Brooks A., Longo D.L., Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 1994, 83:1408-1411.
25. Orabona C., Puccetti P., Vacca C., Bicciato S., Luchini A., Fallarino F., Bianchi R., Velardi E., Perruccio K., Velardi A., Bronte V., Fioretti M.C., Grohmann U. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006, 107:2846-2854.
26. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:2002-2007.
27. Pfefferkorn E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:908-912.
28. Rosenblatt J., Zhang Y.D., Tadmor T. Inhibition of antitumor immunity by B cells. Cancer Res. 2007, 67:5058-5059.
29. Shah S., Divekar A.A., Hilchey S.P., Cho H.M., Newman C.L., Shin S.U., Nechustan H., Challita-Eid P.M., Segal B.M., Yi K.H., Rosenblatt J.D. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 2005, 117:574-586.
30. Sharma M.D., Baban B., Chandler P., Hou D.Y., Singh N., Yagita H., Azuma M., Blazar B.R., Mellor A.L., Munn D.H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 2007, 117:2570-2582.
31. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991, 5:2516-2522.
32. Terness P., Bauer T.M., Rose L., Dufter C., Watzlik A., Simon H., Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002, 196:447-457.
33. Turcotte S., Forget M.A., Beauseigle D., Nassif E., Lapointe R. Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer. Neoplasia 2007, 9:788-796.
34. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
35. Vacca C., Fallarino F., Perruccio K., Orabona C., Bianchi R., Gizzi S., Velardi A., Fioretti M.C., Puccetti P., Grohmann U. CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig. Microbes Infect. 2005, 7:1040-1048.
36. Vinay D.S., Kim C.H., Chang K.H., Kwon B.S. PDCA expression by B lymphocytes reveals important functional attributes. J. Immunol. 2010, 184:807-815.
37. Wingender G., Garbi N., Schumak B., Jungerkes F., Endl E., von B.D., Steitz J., Striegler J., Moldenhauer G., Tuting T., Heit A., Huster K.M., Takikawa O., Akira S., Busch D.H., Wagner H., Hammerling G.J., Knolle P.A., Limmer A. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 2006, 36:12-20.